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Pathwaysa b s t r a c t
One of the challenging problems in drug discovery is to identify the novel targets for drugs. Most of the
traditional methods for drug targets optimization focused on identifying the particular families of ‘‘drug-
gable targets’’, but ignored their topological properties based on the biological pathways. In this study, we
characterized the topological properties of human anticancer drug targets (ADTs) in the context of biolo-
gical pathways. We found that the ADTs tended to present the following seven topological properties:
inﬂuence the number of the pathways related to cancer, be localized at the start or end of the pathways,
interact with cancer related genes, exhibit higher connectivity, vulnerability, betweenness, and closeness
than other genes. We ﬁrst ranked ADTs based on their topological property values respectively, then
fused them into one global-rank using the joint cumulative distribution of an N-dimensional order statis-
tic to optimize human ADTs. We applied the optimization method to 13 anticancer drugs, respectively.
Results demonstrated that over 70% of known ADTs were ranked in the top 20%. Furthermore, the perfor-
mance for mercaptopurine was signiﬁcant: 6 known targets (ADSL, GMPR2, GMPR, HPRT1, AMPD3,
AMPD2) were ranked in the top 15 and other four out of the top 15 (MAT2A, CDKN1A, AREG, JUN) have
the potentialities to become new targets for cancer therapy.
 2015 Elsevier Inc. All rights reserved.1. Introduction
The identiﬁcation of novel drug targets is a major challenge in
medicine and biology. Traditionally, most studies have focused
on the identiﬁcation of particular families of ‘‘druggable targets’’
and achieved signiﬁcant success [1,2]. However, genes rarely func-
tion in isolation in a complex biological system, especially when a
patient undergoes drug treatment (such as the anticancer therapy).
A growing body of evidence indicate that drug design should focus
on all the drug-affected genes simultaneously from the genome-
wide perspective [3]. Recently, with the development of
high-throughput biological experimental technologies, a large col-
lection of gene expression proﬁles with drug treatments is avail-
able, such as the Connectivity Map (CMap) [4]. Many expression-based approaches have emerged for further understanding of drug
mechanisms in the whole genome [5–7]. These methods have pri-
marily focused on single drug target without considering the inter-
actions among them. Studies have demonstrated that the drugs
affect not only their intended targets but also other genes that
interact with them or trigger the downstream molecular events
[8]. The increasing use of protein–protein interactions (PPIs)
allowed for network-based approach to predict novel drug targets
[9–11]. These studies showed that some topological properties,
including betweenness, closeness and connectivity, within pro-
tein–protein network could distinguish known ADTs from other
genes signiﬁcantly. Thus, the topological properties within pro-
tein–protein network can be used to better assess the potentiality
of a node as a novel drug target [9–11].
Biological pathways that belong to more accurate
network-based data have superior properties that naturally suited
to discover novel drug targets [12,13]. Firstly, the pathways were
reliable because they were curated manually from scientiﬁc
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was convenient to consider a pathway in isolation as a particular
function module [15,16]. Thus, it was feasible to map the drug tar-
gets into certain pathways to elucidate the mechanisms of action
of the drug. Finally, the biological pathways were directional. So,
it was practical to assess the importance of the potential drug tar-
gets according to its position or interaction [16,17]. For example,
the insulin receptor (INSR), which was involved in the insulin path-
way and the adherens junction pathway, plays a more important
role in insulin pathway due to its terminal position and high con-
nectivity compared to its role in adherens junction pathway [18].
Taken together, the biological pathways are highly valuable and
powerful for optimization of the drug targets.
In this study, we carefully analyzed the topological properties of
human ADTs in the context of biological pathways and found seven
topological properties that could distinguish known ADTs from
other genes signiﬁcantly. We proposed an optimization approach
for human ADTs through integrating all seven pathway-level topo-
logical properties to rank the candidate ADTs. Our pathway-based
method can help solve some limitations of PPI-based methods,
including (1) the lack of consideration regarding the functional
module in which several genes carry out a speciﬁc function
together, (2) the difﬁculty in understanding the global importance
of any gene in one module or across all of these various functional
modules, (3) the directionless assessment of information transfer
across the genes in functional module. We applied this method
to 13 anticancer drugs respectively, and achieved good optimiza-
tion, particularly for the drugs mercaptopurine and methotrexate.
In conclusion, the optimization strategy we developed, which was
based on pathway-level topological properties, offers a new sight
and could aid in the discovery of novel anticancer drug targets.2. Materials and methods
2.1. Datasets
2.1.1. Known anticancer drug targets (ADTs)
The drug targets dataset was downloaded from the KEGG and
DrugBank database [14,19]. We extracted all the anticancer drugs
and their targets according to the disease and the Anatomical
Therapeutic Chemical (ATC) information. Finally, we obtained
573 ‘‘anticancer drug–target’’ relationships and 155 targets.2.1.2. Four types of special neighbor genes
To test whether the known ADTs interacted with the cancer
related genes, cancer genes (CGs), cancer hallmark genes (CHMGs),
known anticancer drug target genes (KADTGs) and genes encoding
the nuclear membrane proteins (NMPGs) were used as four types
of special neighbor genes, which were important for cancer ini-
tiation, progression and therapy in the following analysis.
766 CGs were obtained from the report by Li et al. [20]. CHMGs
in the study were deﬁned as genes functionally involved in the six
cancer hallmarks, including self-sufﬁciency in growth signals,
insensitivity to antigrowth signals, evasion of apoptosis, limitless
replicative potential, sustained angiogenesis, tissue invasion and
metastasis [21]. We obtained 1320 genes as CHMGs, which were
functionally annotated with ‘‘DNA repair’’, ‘‘cell growth’’, ‘‘cell pro-
liferation’’, ‘‘angiogenesis’’, ‘‘cell migration’’, and ‘‘locomotion’’
from Gene Ontology (GO) [22]. KADTGs mean genes known as anti-
cancer drug targets, we obtained 155 KADTGs from KEGG and
DrugBank. NMPGs mean genes that encode the nuclear membrane
proteins. In particular, we selected 149 NMPGs with a nuclear
membrane subcellular location from the Uniprot Knowlegebase
(UniprotKB) [23].2.1.3. Biological pathways
Information regarding the biological pathways was obtained
from the KEGG PATHWAY database [14], including metabolic and
non-metabolic pathways. We used the R-based software package
SubpathwayMiner to reconstruct all pathways graphically [15].
This type of reconstruction retains the raw information of the path-
ways, particularly the structures, and provides detailed and reli-
able information for analyzing the ADT topological properties
based on these biological pathways.
2.1.4. Anticancer drug gene expression data
In order to optimize the targets for anticancer drugs from the
whole genome, we utilized transcriptional data for cultured human
cancer cells treated with anticancer drugs obtained from CMap
(http://www.broadinstitute.org/cmap/). The library contains 6100
instances of 4 cancer cell lines treated with 1309 distinct small
molecules [4]. We downloaded all the instances, gene expression
proﬁles and their associated annotation ﬁle ‘‘cmap_in-
stances_02.xls’’ from the CMap website. According to the annota-
tion information, 42 among the 1309 bioactive small molecules
were anticancer drugs. The instance information that these drugs
corresponded to were used to extract the anticancer drug gene
expression data.
2.1.5. Gene expression proﬁles of cancers with the survival time
information
To validate that the candidate targets with prior rank have
closely correlation with cancer patients’ survival time, we down-
loaded 9 gene expression proﬁles of cancers with the survival time
information from GEO database (http://www.ncbi.nlm.nih.gov/-
geo/): 3 lung adenocarcinoma proﬁles (GSE13213, GSE3141,
GSE8894), 3 breast cancer proﬁles (GSE2990, GSE4922, GSE1456),
and 3 colon cancer proﬁles (GSE12945, GSE17536, GSE14333).
2.2. Methods
2.2.1. Identifying candidate targets for anticancer drugs
We identiﬁed the candidate targets for each anticancer drug
according to its expression proﬁles from the CMap database [24].
For each instance of drug, we matched perturbation and control
pairs of expression proﬁles according to descriptions of the
instances in the ﬁle ‘‘cmap_instances_02.xls’’. Then we used
fold-change analysis to identify differentially expressed genes
(DEGs) for each instance with |log2fold-change|>log21.5 (gene
expression up-regulated or down-regulated 1.5 folds) between
the corresponding treatments and control gene expression proﬁles.
The DEGs were merged if the corresponding instances belonged to
the same drug, these genes were considered to be anticancer drug
affected genes. As a result, of 42 anticancer drugs in CMap, we
obtained the corresponding 13,082 DEGs which were signiﬁcantly
affected by at least two anticancer drugs. An anticancer drug can
correspond to 1345 genes on average. They were considered as
the candidate targets for anticancer drug and were used to identify
the cancer related crucial pathways.
2.2.2. Identifying cancer related crucial pathways (CRCPs)
The pathways that satisﬁed the following three rules were con-
sidered to be CRCPs: associated with cancer initiation and progres-
sion; important for cancer therapy; and prone to be affected by the
anticancer drugs. Subsequently, we performed pathway annotated
analysis for three gene sets: cancer gene set (766 genes), known
ADT gene set (155 genes), and anticancer drug affected gene set
(13082 genes). The concurrently annotated pathways for these
three gene sets were regarded as the CRCPs and used for analyzing
the topological properties of the known ADTs.
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For each gene in CRCPs, we calculated the following seven path-
way-level topological properties: (1) the number of CRCPs inﬂu-
enced; (2) the positional tendency: We divided each CRCP into
three kinds of positions: start, median and end. According to the
degree distribution of all nodes (genes) in CRCP, the nodes with 0
in-degree and their immediate neighbors were deﬁned as the
nodes located at start position, the nodes with 0 out-degree and
their immediate neighbors were deﬁned as the nodes located at
end position, and the remaining nodes were deﬁned as the nodes
located at median position; (3) the extent of the four types of spe-
cial neighbor genes (CGs, CHMGs, KADTGs, NMPGs) simultaneous-
ly existed; (4) the average connectivity across all CRCPs; (5) the
average betweenness across all CRCPs; (6) the average closeness
across all CRCPs; (7) the average vulnerability across all CRCPs:
For each CRCP, the vulnerability was calculated based on the global
efﬁciency characteristics [25] which denotes the efﬁciency of the
CRCP in sending information between the nodes. We calculated
the average vulnerability for each gene across all CRCPs which it
inﬂuenced. The corresponding formulas and short descriptions
are listed in Table 1 and the detailed descriptions are shown in
Supplementary Information.
2.2.4. Optimizing candidate ADTs based on pathway-level topological
properties
The selection of a prospective ADT is a complex balance in
which numerous conditions were considered. We compared all of
the seven pathway-level topological properties simultaneously to
rank the candidate ADTs like the method of Endeavor [26].
Speciﬁcally, we used the order statistics to combine the seven dif-
ferent ranks from the seven pathway-level topological property
values. A ‘‘M’’ statistic was computed from all seven rank ratios
using the joint cumulative distribution of an N-dimensional order
statistic.
Mðr1; r2;    ; rNÞ ¼ N!
XN
i¼1
ðrNiþ2  rNiÞMðr1; r2;    ; rNi; rNiþ2;    rNÞ
ð1Þ
where ri is the rank ratio for the ith pathway-level topological prop-
erty, and N is the number of properties used (here, N = 7).
2.2.5. Survival analysis
For each anticancer drug, we selected top 20% candidate targets
as the biomarkers to perform the survival analyses. For a gene
expression proﬁle of cancers with the survival time information,
the cancer patients were clustered into two groups according to
the biomarker genes’ expression using the k-means clustering
method [27]. Then, according to the survival information of the
cancer patients, we created the survival curves for the above twoTable 1
List of pathway-level topological properties.
Property Function
Cancer related crucial pathway number (CRCPN) Ng






















Average closeness (AC) 1
N
PN
i¼1jVg j  1=
P
g–jdgj
Average vulnerability (AV) 1
N
PN
i¼1ðE Eðg; iÞÞ=Egroups. The survival curves were compared with the log-rank test
and got a p-value [27]. The smaller the p-value the more closely
correlated with the cancer patient survival time for the biomarkers
(top candidate targets). Here, we used the survival package for the
R statistical computing platform.3. Results
3.1. Human ADT topological properties in the context of biological
pathways
The biological pathways themselves provide valuable informa-
tion in drug targets identiﬁcation and optimization. Our current
aim is to optimize the targets for anticancer drugs. So, we focused
on the biological pathways associated with cancer. We selected the
cancer related crucial pathways (CRCPs). The pathways that satis-
ﬁed the three rules were considered as CRCPs: they are associated
with cancer initiation and progression; important for cancer ther-
apy; prone to be affected by anticancer drugs (see details in Sec-
tion 2.2). Totally, we identiﬁed 119 CRCPs, including purine
metabolism, arachidonic acid metabolism, MAPK signaling path-
way, ErbB signaling pathway, etc. Most of them are closely associ-
ated with the cancer initiation, progression, and therapy [28–30].
We then characterized the topological properties of the known
ADTs in the context of these CRCPs, including: the number of
CRCPs they inﬂuenced; their positional tendency; their interac-
tions with cancer related genes; their betweenness, closeness,
connectivity and vulnerability. We used the following seven mea-
surements to quantify the above topological properties respective-
ly, called CRCPN, APS, ASNS, AB, AC, AD, and AV (see Table 1 and
Supplementary Methods for detailed formulas and descriptions).
As shown in Table 2, the CRCPN of known ADTs was signiﬁcantly
higher than that of control set (all genes in all CRCPs) (P-val-
ue = 1.98e08, the signiﬁcance was calculated using the Wilcoxon
Rank-Sum test unless otherwise noted). On average, the CRCPN of
the known ADTs was two times as much as that of control set, and
over half of known ADTs participated in over three CRCPs. This sug-
gests that the ADTs tend to inﬂuence a greater number of pathways
associated with cancer. Ille et al. also reported that multi-pathway
proteins presented to be good potential drug targets [11].
For one gene, its function and importance may vary according
to its location in the pathway. To test whether the ADT positional
tendency differed from other genes, we divided each CRCP into
three kinds of positions: start, median, and end. We quantiﬁed
them by the measurements of APS, called: APS_start, APS_median,
and APS_end. The results demonstrated that, compared with con-
trol set, the known ADTs tended to be localized to the start or
end of CRCPs (P-value = 0.02; P-value = 8.52e3). This implied that
the ADTs were prone to be localized to the gate of the biologicalDescription
The number of cancer related crucial pathways which gene g inﬂuenced
PSðg; t; iÞ denotes whether gene g locates at t position in ith CRCP; t = terminal
(start or end)
NSðg; k; iÞ denotes whether there exists the type k neighbor in ith CRCP for gene g
Kðg; iÞ denotes the number of links to gene g in ith CRCP
dpq is the number of shortest paths from gene p to gene q; dpq(g) is the number of
shortest paths from gene p to gene q that pass through gene g; V denotes the set
of all genes for ith CRCP
|Vg| denotes the size of the reachable sub-CRCP for ith CRCP from gene g; dgj is
the distance between gene g and gene j
Eðg; iÞ denotes the global efﬁciency of the ith CRCP when delete gene g and all of
its links; E is the global efﬁciency of the whole ith CRCP
Table 2
Signiﬁcant differences of pathway-level topological properties between controls and
known ADTs. The signiﬁcance was calculated using the Wilcoxon Rank-Sum test
unless otherwise noted.
Property Mean in controls Mean in known ADTs Signiﬁcance
CRCPN 2.7577 5.6777 P = 1.9E08
APS_start 0.2700 0.2941 P = 2.8E02
APS_median 0.5899 0.5834 P = 0.67230
APS_end 0.2710 0.2962 P = 8.5E03
ASNS_cgs 0.5188 0.6006 P = 4.4E02
ASNS_chmgs 0.0514 0.1146 P = 8.9E10
ASNS_kadtgs 0.2381 1.0000 P = 6.3E76
ASNS_nmpgs 0.5179 0.7266 P = 1.9E05
AD 2.7053 4.0535 P = 1.5E05
AB 38.809 201.92 P = 7.5E08
AC 0.0698 0.0724 P = 2.8E02
AV 0.0098 0.0307 P = 1.3E05
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bined these two kinds of positions into one category, called ‘‘termi-
nal’’ and utilized the measurement of ATPS to quantify it (see
Table 1).
Genes rarely perform their function in isolation underlying the
pathways; the neighboring interactions potentially determine
their importance to a certain extent [18]. We investigated whether
there is a special relationship with the neighbors in proximity to
the known ADTs. To test this, we chose four types of genes impor-
tant for cancer initiation, progression, and therapy: CGs, CHMGs,
KADTGs, NMPGs [20–23]. We used ASNS_cgs, ASNS_chmgs,
ASNS_kadtgs, and ASNS_nmpgs to quantify them, respectively
(see Supplementary Methods for detailed formulas and descrip-
tions). As shown in Table 2, compared with control set, it was more
likely that the known ADTs interacted with other known ADTs (P-
value = 6.34e76) and the cancer genes (P-value = 0.04). In addi-
tion, the known ADTs tended to regulate the downstream cancer
hallmark genes to a greater extent than control set (P-val-
ue = 8.93e10). Hanahan et al. reported that the anticancer drugs,
which could target each of the cancer hall-mark (CHM) capa-
bilities, were required [21]. Therefore, if the CHMs were regulated
by the ADTs it would help prevent incipient cancer from progress-
ing. Moreover, the known ADTs also tended to regulate the down-
stream NMPGs more likely than that of control set (P-
value = 1.87e05). Nuclear membrane proteins play key roles for
the signals transferred into the nucleus from the cytoplasm. Thus,
it will be helpful for the information dissemination of the cancer
therapy if the NMPGs were regulated by the ADTs. Taken together,
it could be potentially helpful for cancer therapy if these four types
of special neighbors are simultaneously present around the ADTs.
Thus, we considered the four types of neighbors that could be
simultaneously present and used the measurement of AFSNS to
quantitate this analysis (see Table 1).
Additionally, we analyzed four other basic topological proper-
ties that reﬂected the importance of a certain gene or protein
across the CRCPs: betweenness, closeness, connectivity and vul-
nerability. As shown in Table 2, the betweenness and connectivity
of the known ADTs were much greater compared to the control set
(P-value = 1.50e05; P-value = 7.55e08). This suggests that the
known ADTs are more likely to be the hub-bottlenecks in CRCPs;
previous studies have also shown that the known drug targets
tended to have more neighbors [9] and to bridge two or more clus-
ters in PPIs [31]. Moreover, we found that the known ADTs had the
tendency to have higher closeness (P-value = 0.028), indicating
that the known ADTs may potentially inﬂuence other molecules
more rapidly in the CRCPs. The signiﬁcantly higher vulnerability
(P-value = 1.34e05) of known ADTs also suggested their critical
roles in sending information in the whole CRCP, of which the dele-
tion would result in a lower level of communication.3.2. Optimize ADTs based on the topological properties underlying the
biological pathways
Selection of prospective ADTs is a delicate balance in which
numerous conditions should be considered. In order to optimize
the human ADTs systematically, we considered all above seven
properties that the ADTs shared in the level of biological pathways
simultaneously to rank the candidate ADTs. Ultimately, using the
method of Endeavor [26], seven distinct prioritizations were gener-
ated for each candidate ADT and then fused into one global-rank
(see Section 2.2 for detail optimization pipeline). We applied this
optimization method to 13 anticancer drugs, respectively, and
affected genes of each anticancer drug that mapped into CRCPs
were considered as its candidate targets. As shown in Fig. 1, over
70% of known ADTs on average were ranked in the top 20%.
Speciﬁcally, for 10 of the 13 anticancer drugs, half of their known
targets ranked in the top 20%. Moreover, 6 of these 10 drugs (aza-
citidine, carmustine, geﬁtinib, methotrexate, nilutamide, thalido-
mide) exhibited a good performance that all of their known
targets were ranked in the top 20%. We analyzed the top 30% can-
didate ADTs for each anticancer drug. Result showed there were 12
drugs having over 50% known ADTs appeared in the top 30%. Fur-
thermore, there were 8 drugs having all known ADTs also appeared
in the top 30%. Over 50% of known ADTs for each of these 12 drugs
and all known ADTs for these 8 drugs appeared in the top 30% sug-
gesting that most of the known ADTs can be efﬁciently recalled
according to our approach. To quantify the probabilities of the
known ADTs appeared ahead, we calculated the ratio of the
observed to expected number of known targets (called OER) for
the 13 anticancer drugs, respectively. As shown in Fig. 2, the OERs
were signiﬁcantly increased along with an increase in global-rank.
In particular, the maximum probability of known ADTs in the top
10% was 5.3 times as much as expected indicating the potency of
candidate ADTs with prior global-rank to exhibit a greater likeli-
hood of being novel ones.
Furthermore, based on the expression, a potentially useful ADT
should be able to aid in the determination of cancer patients’ sur-
vival time. Thus, to validate if the genes with prior global-ranks
have a strong association with cancer patients’ survival time, we
downloaded nine gene expression proﬁles of cancer cases with
patient survival time information from the GEO database: three
lung adenocarcinoma proﬁles, three breast cancer proﬁles, and
three colon cancer proﬁles (see details in Datasets). For each anti-
cancer drug, we selected the candidate targets with high ranks (top
20%) and performed the survival analysis (see details in Datasets).
We found that the candidate targets with prior ranks were closely
associated with the survival time (p 6 0.05, log-rank test) (Fig. 3a).
In addition, a survival analysis was constructed for the bottom 20%
of candidate targets, but the associations with survival time were
not as strong as for targets ranked ahead, and the difference was
signiﬁcant (Fig. 3b and c). This ﬁnding indicated that priorization
of the candidate targets based on the pathway-level topological
properties is reliable. In order to further illustrate the effect and
power of our method in optimizing ADTs, we analyzed the next
two anticancer drugs: mercaptopurine and methotrexate.
Mercaptopurine, a purine analogue interfering with nucleic acid
biosynthesis by inhibiting purine metabolism, is used to prevent
the formation and spread of cancer cells. According to the records
in Drug Bank and KEGG, it has 12 known targets. We identiﬁed 108
candidate targets which were mapped into 96 CRCPs according to
our method. Eleven of 12 known targets were ranked within the
top 30 among the list of 108 genes. Moreover, six of 12 known tar-
gets were ranked within the top 15 (Table 3). Other 9 candidate
targets were also reported as potential novel targets for mercap-
topurine. The top ranked known targets, adenylosuccinate lyase
(ADSL), was involved in the purine metabolism pathway and its
Fig. 1. The ratios of known ADTs which ranked in top 20% and top 30% of candidate targets list for 13 anticancer drugs.
Fig. 2. The OER values for 13 anticancer drugs. The horizontal axis denotes each 10
percents of candidate ADTs ordered by global-rank, and the vertical axis denotes the
OER values for 13 anticancer drugs. The dash line indicates that the higher-ranked
candidates were more likely to be the known ADTs. The solid line shows the average
OER.
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instance, the known targets adenylosuccinate synthase (ADSS) was
an upstream neighbor and AMP deaminase was a downstream one;
the cancer gene deoxycytidine kinase (DCK) and the cancer
hallmark gene adenosine kinase (ADK) were in downstream
(Supplementary Fig. 1). Methionine adenosyltransferase II-alpha
(MAT2A), ranked second, was not described as a known target
for mercaptopurine according to the Drug Bank and KEGG databas-
es. This suggested that MAT2A may be a new target of Mercaptop-
urine. We found that MAT2A was reported to play an important
role in facilitating cancer growth. Its expression was increased in
cancer cells such as liver and colon cancer and it may hold potency
as a new target for antineoplastic therapy [32,33]. Liu et al. sug-
gested that the down regulation of MAT2A potentially inhibited
the liver cancer growth [32]. Interestingly, according to the CMap,
MAT2A was signiﬁcantly down-regulated by the stimulus of mer-
captopurine. This indicated that MAT2A exhibited strong potential
as a novel target for mercaptopurine. Cyclin-dependent kinase
inhibitor 1A (CDKN1A, p21), amphiregulin (AREG), and jun proto-
oncogene (JUN) ranked sixth, tenth and eleventh, respectively, as
shown in Fig. 4, were involved in the ErbB signaling pathway
simultaneously, and all of them were located in terminal positions
(inlet or outlet of the signals ﬂuxing through the pathway). The
dysregulation of the ErbB signaling pathway has a strong asso-
ciation with multiple cancers [34,35] and Shah et al. proposed that
targeting the ErbB signaling could potentially serve as a therapy for
management of prostatic cancer [36]. The AREG, one of the ligands
of the epidermal growth factor receptor (EGFR), participates in ﬁve
Fig. 3. (A) Distribution of survival analysis P-values for 13 anticancer drugs using the top 20% candidate targets. 11 Among 13 anticancer drugs achieved statistical
signiﬁcance. (B) Distribution of survival analysis P-values for 13 anticancer drugs using the lowest 20% candidate targets. None of the 13 anticancer drugs achieved the
statistical signiﬁcance. (C) Ratio of expression proﬁles with the survival analysis P-values 6 0.05 using the highest and lowest 20% candidate targets respectively. The top
candidates exhibited a signiﬁcant correlation with survival times (long and short) for more proﬁles than the lowest candidates.
Table 3
The information of top candidate targets for mercaptopurine and methotrexate.
Top 15 for mercaptopurine Top 5 for methotrexate
Symbol Rank Ref. Symbol Rank Ref. Symbol Rank Ref.
ADSL 1 Known TCF7L2 8 [48] CTH 1 –
MAT2A 2 [32,33] CALML5 9 [49] MTR 2 –
RET 3 [50] AREG 10 [37,38] CDC6 3 [51]
GMPR2 4 Known JUN 11 [39] PLCD1 4 [45]
GMPR 4 Known HPRT1 12 Known DHFR 5 Known
AURKA 5 [52] AMPD3 13 Known
CDKN1A 6 [40] AMPD2 13 Known
CDKN1C 7 [53]
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evading apoptosis, limitless replicative potential, sustained angio-
genesis, tissue invasion and metastasis [37]. Due to its multiple
functions in tumorigenesis, AREG exhibits a promising target for
cancer treatment. Furthermore, Busser et al. suggested that it
was required to target the expression or activity of AREG in cancer
treatment [38]. According to the CMap, AREG was signiﬁcantly
down-regulated under the stimulus of mercaptopurine. This indi-
cated that the ErbB signaling might be partly inhibited by the treat-
ment of mercaptopurine against AREG. Additionally, the other two
candidate targets, JUN and p21, were also implicated in a variety of
human cancers [39,40]. Their positions in the ErbB pathway were
crucial: they have the special upstream neighbors such as known
targets and cancer genes, and they were the outlets for the signals
across the whole pathway. Thus, their disturbances directly corre-
lated with the angiogenesis, adhesion, and cell cycle progression
associated with oncogenesis. In summary, our optimization
approach was reliable and signiﬁcant, and the candidate targets
ranked highly in our study could be potential novel targets for
mercaptopurine.
Methotrexate helps to inhibit the growth of cancer cells by pre-
venting the synthesis of DNA and RNA using folate. According to
DrugBank and KEGG databases, there was only one known target,
dihydrofolate reductase (DHFR), that participated in tetrahydrofo-
late synthesis [41]. This means that our method can rank candidate
targets based on an almost blinded information of the known drug
targets. Since our method is effective for the drug with known tar-
gets, it can be applied to new drugs lacking known targets as well.
According to the CMap, we identiﬁed 307 differentially expressedgenes which mapped into 115 CRCPs as the candidate targets of
methotrexate. We optimized the 307 candidate targets based on
our pipeline, and DHFR was ranked ﬁfth (Table 3). The top four
candidate targets were not described as a known target for mer-
captopurine according to the Drug Bank and KEGG databases. Cys-
tathionase (CTH) and 5-methyltetrahydrofolate-homocysteine
methyltransferase (MTR), ranked ﬁrst and second respectively,
participated simultaneously in the selenocompound metabolism
pathway. These two genes encoded the critical enzymes for
biosynthesis of the L-selenomethionine and methylselenol, which
suppress cell growth of several human cancers [42–44]. According
to the CMap, we found that CTH and MTR were signiﬁcantly up-
regulated by the stimulus of methotrexate. This indicated that
methotrexate potentially inhibited the growth and promoted
apoptosis of cancer cells by heightening the concentration of
L-selenomethionine and methylseleno through up-regulation of
CTH or MTR. Thus, CTH and MTR may be potential new targets of
methotrexate. Another top-ranked candidate, phospholipase C-
delta 1 (PLCD1), as a potential novel target [45], was mapped to
three CRCPs: phosphatidylinositol signaling pathway, calcium sig-
naling pathway and inositol phosphate metabolism (Supplemen-
tary Fig. 2). But its importance was different in these three CRCPs
due to its different position. It was located in three critical posi-
tions in the phosphatidylinositol signaling pathway and it was
the essential mediator for the signal ﬂux in this pathway (Supple-
mentary Fig. 2c). The entire phosphatidylinositol signaling path-
way might be heavily perturbed if PLC (encoded by the PLCD1)
were absent. Previous studies have demonstrated that the dys-
regulation of the phosphatidylinositol signaling network may con-
Fig. 4. The visualization of three candidate targets for mercaptopurine involved in the ErbB signaling pathway. AREG ranked tenth, p21 ranked sixth, and c-Jun ranked
eleventh. They were all located at the key positions of the pathway, as gates of the signals inﬂux and efﬂux. Especially the c-Jun and p21; their inhibition or activation
inﬂuenced the downstream biological processes such as angiogenesis, adhesion and cell cycle progression. Node colors: blue, candidate targets; red, known ADTs; green,
cancer genes; pink, cancer hallmark genes. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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niﬁcantly down-regulated genes in it [46]. According to Xiang
et al., PLCD1 could inhibit cancer cell migration and induce the cell
cycle G2/M arrest [47]. Therefore, the up-regulation of PLCD1 could
potentially contribute to cancer therapy. Interestingly, PLCD1 was
also up-regulated by the treatment of methotrexate. Thus, PLCD1
exhibits the strong potential for being a novel target for
methotrexate.4. Discussion
The selection of prospective targets for an anticancer drug
involves multiple considerations. In this article, we characterized
the pathway-level topological properties of ADTs and found that
some topological properties could signiﬁcantly distinguish them
from other genes. The ADTs tend to inﬂuence more cancer related
crucial pathways; they tend to be localized to terminal positions;
they have a greater number of interactions with other known ADTs
and cancer genes; they tend to regulate the cancer hallmark genes
or genes encoded nucleus membrane proteins; they play key roles
in keeping the pathway structure and the information transfer
because of the higher closeness, betweenness, connectivity, andvulnerability. Therefore, we suggest that these pathway-level topo-
logical properties should be considered when optimizing the ADTs.
Based on these pathway-level topological properties, we pro-
vided an optimization method for human ADTs. Nearly 72% of
known ADTs were ranked in the top 20% on average, and almost
80% of known ADTs were ranked in the top 30%. In addition, we
found that the top ranked candidates displayed a close correlation
with the cancer patients’ survival time. Furthermore, we applied
the optimization method to mercaptopurine and methotrexate.
For mercaptopurine, six known targets were ranked in the top 15
candidate targets. Almost all of the other nine were found to be
potential new targets for cancer therapy. For mercaptopurine, the
several top candidate targets ranked by our method were found
to be potential new targets for cancer therapy, although the drug
has an almost blinded information of the known drug targets.
Our results demonstrated that the pathway-level topological prop-
erties we used were informative and practically useful for human
ADT optimization. The optimization method we proposed poten-
tially offers a global insight into the underlying mechanisms of
anticancer drug actions and it could potentially be applied to other
kinds of drugs without prior targets information.
The PPI-based approaches for optimizing anticancer drug
targets has mainly focused on topological features, including
J. Zhang et al. / Journal of Biomedical Informatics 54 (2015) 132–140 139betweenness, closeness and connectivity to assess the potentiality
of a node as a novel drug target. However, they ignored the impor-
tance of a functional module and the direction assessment of infor-
mation transfer across the genes in a functional module. Our
method, a pathway-based approach for optimizing anticancer drug
targets, naturally suited to use information of a functional module
because a pathway is naturally considered as a particular function
module. More importantly, the biological pathways are directed
and thus can be used to assess the importance of the potential drug
targets according to its position. We found that the ADTs tended to
inﬂuence more cancer related pathways and be localized at the
start or end of the pathways and to interact with cancer related
genes. These further suggested that our pathway-based approach
for optimizing anticancer drug targets are highly valuable for the
optimization of drug targets.
We also noted that there were several limitations in our study
due to the uncompleted knowledge of human gene function and
biological pathways. Because our method was based on the
quantitative structures of pathways, the optimization could not
be performed for the candidate ADTs if it was not annotated in
any pathways. These issues will be improved with the develop-
ment of integrated biological molecular networks with multi-
dimensional information; and an optimization pipeline based on
human biological pathways will be expanded. The pathway-based
strategy we reported in this study offers insight toward the discov-
ery of more reliable and effective targets for the anticancer drugs.
Acknowledgments
This work was supported in part by the National Natural
Science Foundation of China (Grant No. 31200996), Yu Weihan
Outstanding Youth Training Fund of Harbin Medical University,
and the Education Department Project of Heilongjiang Province
(Grant no. 12531295).
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jbi.2015.02.007.
References
[1] Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M. Prediction of drug-
target interaction networks from the integration of chemical and genomic
spaces. Bioinformatics 2008;24:i232–40.
[2] Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, Caffrey DR, et al. Structure-
based maximal afﬁnity model predicts small-molecule druggability. Nat
Biotechnol 2007;25:71–5.
[3] Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat
Chem Biol 2008;4:682–90.
[4] Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The
Connectivity Map: using gene-expression signatures to connect small
molecules, genes, and disease. Science 2006;313:1929–35.
[5] Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, et al.
Discovery of drug mode of action and drug repositioning from transcriptional
responses. Proc Natl Acad Sci USA 2010;107:14621–6.
[6] Chen X, Xu J, Huang B, Li J, Wu X, Ma L, et al. A sub-pathway-based approach
for identifying drug response principal network. Bioinformatics
2011;27:649–54.
[7] Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, Bork P. Drug-induced
regulation of target expression. PLoS Comput Biol 2010;6.
[8] Yang L, Chen J, Shi L, Hudock MP, Wang K, He L. Identifying unexpected
therapeutic targets via chemical-protein interactome. PLoS ONE 2010;5:e9568.
[9] Zhu M, Gao L, Li X, Liu Z, Xu C, Yan Y, et al. The analysis of the drug-targets
based on the topological properties in the human protein-protein interaction
network. J Drug Target 2009;17:524–32.
[10] Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drug-target network.
Nat Biotechnol 2007;25:1119–26.
[11] Farkas IJ, Korcsmaros T, Kovacs IA, Mihalik A, Palotai R, Simko GI, et al.
Network-based tools for the identiﬁcation of novel drug targets. Sci Signal
2011;4:pt3.
[12] Apic G, Ignjatovic T, Boyer S, Russell RB. Illuminating drug discovery with
biological pathways. FEBS Lett 2005;579:1872–7.[13] Chen L, Wang Q, Zhang L, Tai J, Wang H, Li W, et al. A novel paradigm for
potential drug-targets discovery: quantifying relationships of enzymes and
cascade interactions of neighboring biological processes to identify drug-
targets. Mol Biosyst 2011;7:1033–41.
[14] Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucl
Acids Res 2000;28:27–30.
[15] Li C, Li X, Miao Y, Wang Q, Jiang W, Xu C, et al. SubpathwayMiner: a
software package for ﬂexible identiﬁcation of pathways. Nucl Acids Res
2009;37:e131.
[16] Li C, Han J, Yao Q, Zou C, Xu Y, Zhang C, et al. Subpathway-GM: identiﬁcation of
metabolic subpathways via joint power of interesting genes and metabolites
and their topologies within pathways. Nucleic Acids Res 2013 May;41:e101.
[17] Liu Wei, Li Chunquan, Yanjun Xu, Yang Haixiu, Yao Qianlan, Han Junwei, et al.
Topologically inferring risk-active pathways toward precise cancer
classiﬁcation by directed random walk. Bioinformatics 2013;29(17):2169–77.
[18] Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, et al. A systems
biology approach for pathway level analysis. Genome Res 2007;17:1537–45.
[19] Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a
knowledgebase for drugs, drug actions and drug targets. Nucl Acids Res
2008;36:D901–6.
[20] Li X, Li C, Shang D, Li J, Han J, Miao Y, et al. The implications of relationships
between human diseases and metabolic subpathways. PLoS ONE
2011;6:e21131.
[21] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
[22] Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, et al. The Gene
Ontology (GO) database and informatics resource. Nucl Acids Res
2004;32:D258–61.
[23] Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, et al. UniProt:
the Universal Protein knowledgebase. Nucl Acids Res 2004;32:D115–9.
[24] Li Chunquan, Shang Desi, Wang Yan, Li Jing, Han Junwei, Wang Shuyuan, et al.
Characterizing the network of drugs and their affected metabolic
subpathways. PLoS ONE 2012;7:e47326.
[25] Gol’dshtein V, Koganov G, Surdutovich G. Vulnerability and hierarchy of
complex networks. Arxiv PreprCond-Mater 2004:0409298.
[26] Aerts S, Lambrechts D, Maity S, Van Loo P, Coessens B, De Smet F, et al.
Gene prioritization through genomic data fusion. Nat Biotechnol
2006;24:537–44.
[27] Zhang Chunlong, Li Chunquan, Li Jing, Han Junwei, Shang Desi, Zhang
Yunpeng, et al. Identiﬁcation of miRNA-mediated core gene module for
glioma patient prediction by integrating high-throughput miRNA, mRNA
expression and pathway structure. PLoS ONE 2014;9(5):e96908.
[28] Marinello E, Carlucci F, Rosi F, Floccari F, Raspadori D, Tabucchi A. Purine
metabolism in B-cell lymphocytic leukemia: a microarray approach. Nucleos
Nucleot Nucl Acids 2006;25:1277–81.
[29] Hyde CA, Missailidis S. Inhibition of arachidonic acid metabolism and its
implication on cell proliferation and tumour-angiogenesis. Int
Immunopharmacol 2009;9:701–15.
[30] Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine
resistance associated with activated ErbB system in breast cancer cells is
reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer
2010;126:545–62.
[31] Yao L, Rzhetsky A. Quantitative systems-level determinants of human genes
targeted by successful drugs. Genome Res 2008;18:206–13.
[32] Liu Q, Wu K, Zhu Y, He Y, Wu J, Liu Z. Silencing MAT2A gene by RNA
interference inhibited cell growth and induced apoptosis in human hepatoma
cells. Hepatol Res 2007;37:376–88.
[33] Chen H, Xia M, Lin M, Yang H, Kuhlenkamp J, Li T, et al. Role of methionine
adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced
growth of human colon cancer cells. Gastroenterology 2007;133:207–18.
[34] Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol
Cell Biol 2006;7:505–16.
[35] Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer.
Curr Opin Cell Biol 2009;21:177–84.
[36] Shah RB, Ghosh D, Elder JT. Epidermal growth factor receptor (ErbB1)
expression in prostate cancer progression: correlation with androgen
independence. Prostate 2006;66:1437–44.
[37] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell
2011;144:646–74.
[38] Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of
amphiregulin in human cancer. Biochim Biophys Acta 2011;1816:119–31.
[39] Shaulian E. AP-1–The Jun proteins: oncogenes or tumor suppressors in
disguise? Cell Signal 2010;22:894–9.
[40] Abbas T, Dutta A. P21 in cancer: intricate networks and multiple activities. Nat
Rev Cancer 2009;9:400–14.
[41] Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG.
Interaction of dihydrofolate reductase with methotrexate: ensemble and
single-molecule kinetics. Proc Natl Acad Sci USA 2002;99:13481–6.
[42] Sanmartin C, Plano D, Palop JA. Selenium compounds and apoptotic
modulation: a new perspective in cancer therapy. Mini Rev Med Chem
2008;8:1020–31.
[43] Zeng H, Wu M, Botnen JH. Methylselenol, a selenium metabolite, induces cell
cycle arrest in G1 phase and apoptosis via the extracellular-regulated kinase 1/
2 pathway and other cancer signaling genes. J Nutr 2009;139:1613–8.
[44] Krittaphol W, McDowell A, Thomson CD, Mikov M, Fawcett JP.
Biotransformation of L-selenomethionine and selenite in rat gut contents.
Biol Trace Elem Res 2011;139:188–96.
140 J. Zhang et al. / Journal of Biomedical Informatics 54 (2015) 132–140[45] Fu L, Qin YR, Xie D, Hu L, Kwong DL, Srivastava G, et al. Characterization of a
novel tumor-suppressor gene PLC delta 1 at 3p22 in esophageal squamous cell
carcinoma. Cancer Res 2007;67:10720–6.
[46] Danielsen SA, Cekaite L, Agesen TH, Sveen A, Nesbakken A, Thiis-Evensen E,
et al. Phospholipase C isozymes are deregulated in colorectal cancer–insights
gained from gene set enrichment analysis of the transcriptome. PLoS ONE
2011;6:e24419.
[47] Xiang T, Li L, Fan Y, Jiang Y, Ying Y, Putti TC, et al. PLCD1 is a functional tumor
suppressor inducing G(2)/M arrest and frequently methylated in breast cancer.
Cancer Biol Ther 2010;10:520–7.
[48] Jingushi K, Takahashi-Yanaga F, Yoshihara T, Shiraishi F, Watanabe Y, Hirata M,
et al. DIF-1 inhibits the Wnt/beta-catenin signaling pathway by inhibiting
TCF7L2 expression in colon cancer cell lines. Biochem Pharmacol
2011;83:47–56.[49] Rogers MS, Strehler EE. The tumor-sensitive calmodulin-like protein is a
speciﬁc light chain of human unconventional myosin X. J Biol Chem
2001;276:12182–9.
[50] Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets.
Mod Pathol. 2008;21(Suppl. 2):S37–43.
[51] Feng CJ, Li HJ, Li JN, Lu YJ, Liao GQ. Expression of Mcm7 and Cdc6 in oral
squamous cell carcinoma and precancerous lesions. Anticancer Res
2008;28:3763–9.
[52] Barton VN, Foreman NK, Donson AM, Birks DK, Handler MH, Vibhakar R.
Aurora kinase A as a rational target for therapy in glioblastoma. J Neurosurg
Pediatr 2010;6:98–105.
[53] Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, et al. Down-regulation of
p57Kip2 induces prostate cancer in the mouse. Cancer Res 2008;68:3601–8.
